TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference
TRACON Pharmaceuticals (TCON) announced that CEO Charles Theuer will present a corporate overview at the 2020 Wells Fargo Virtual Healthcare Conference on September 9 at 10:40 am EDT. The company focuses on developing targeted cancer therapies and operates an efficient, CRO-independent product development platform. Its pipeline includes Envafolimab for sarcoma, TRC253 for prostate cancer, TRC102 for lung cancer, and TJ004309 for advanced solid tumors. TRACON seeks partnerships for U.S. regulatory and clinical development to share costs and risks.
- None.
- None.
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the 2020 Wells Fargo Virtual Healthcare Conference on Wednesday, September 9th, at 10:40 am EDT.
To access a live webcast of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a subcutaneous PD-L1 single-domain antibody being developed for the treatment of sarcoma with the goal of initiating a registrational trial in the U.S. in the fourth quarter of 2020; TRC253, a small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate being developed for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Mark Wiggins | Andrew McDonald |
| Chief Business Officer | LifeSci Advisors LLC |
| (858) 251-3492 | 646-597-6987 |
| mwiggins@traconpharma.com | Andrew@lifesciadvisors.com |
FAQ
When will TRACON Pharmaceuticals present at the Wells Fargo Virtual Healthcare Conference?
Who is the CEO of TRACON Pharmaceuticals?
What is the focus of TRACON Pharmaceuticals?
What products are in TRACON Pharmaceuticals' pipeline?
How can I access the live webcast for TRACON Pharmaceuticals' presentation?
